



Point of Care Technology – Why Knowing Now Matters in the ED

Ellis Jacobs, Ph.D., DABCC, FACB

Director, Scientific Affairs, Abbott Rapid Diagnostics

Adjunct Associate Professor of Pathology, Mount Sinai School of Medicine

ASCLS 2017 Northwest Medical Laboratory Symposium

Newport News, VA

20 | Apr | 2018

Agenda

1 Emergency Department Facts and Figures

2 Why knowing now matters for Chest Pain



3 Why knowing now matters for Sepsis

4 Why knowing now matters for Infectious Disease

There are data in this presentation that are taken from individual published studies. They are individual evaluations and are not meant to replace or represent product claims which are found in the package inserts.

ED Stats: 2011

>136 MM ED visits = 44.5 visits/100 persons/year




http://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2011_ed_web_tables.pdf



ED Stats: 2011

>136 MM ED visits = 44.5 visits/100 persons/year

% of EDs



http://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2011_ed_web_tables.pdf

ED: 2015



Approximately **three-quarters** of emergency room (ER) physicians **have seen increases** in patient visits since January 2014.



In addition to a national shortage of primary care doctors, experts cite a **lack of physicians willing to accept Medicaid patients** as contributing factors to increased ER usage.

7 in 10

survey respondents to a ACEP survey say **their emergency departments are not ready** for continuing, and potentially significant, increases in volume.

Delay in the ED Leads to Poor Outcomes

71%-79%

higher likelihood of death when ED length of stay is greater than 6 hours¹

20% increase

in risk of death for every hour an ED patient waits²

10% increase

In risk of death for a one hour increase in overall length of ED stay²

1. BMJ (2011) 342: d2983

2 MJA (2006) 182: 208-212

3 Ann Emerg Med. (2007); 50; 489-96

Long ED stay leads to worse adherence to ACC/AHA guideline care for NSTEMI patients³



Aspirin

β-blockers





Heparin

GP II/IIIa inhibitors

Clopidigrel




Theoretical TAT Impact on ED Operations



Why knowing now matters in the ED - Chest Pain

Challenges in Chest Pain Triage



For patients 45+ years old, non-specific chest pain is the most common ED presentation resulting in discharge



Chest Pain Could Be....

Heart	Gastro-intestinal	Lung	Muscle/Bone	Other
Heart attack	Acid reflux (heartburn)	Pneumonia	Bruised or broken ribs	Shingles
Angina	Swallowing problems related to disorders of the esophagus	Viral bronchitis	Sore muscles from exertion or chronic pain syndromes	Panic attack
Pericarditis	Gallstones or inflammation of the gallbladder or pancreas	Pneumothorax	Compression fracture, causing pressure on a nerve	
Myocarditis				
Cardiomyopathy				
Aortic dissection				



NSTEMIs Are Not Just Chest Pain

COMMONLY:

- Chest pain or discomfort
- Upper body discomfort
- Shortness of breath

BUT CONSIDER....

- Pain and discomfort could be mild, and could come and go over hours
- Diabetics may have no, or very mild, symptoms
- Cold sweat
- Nausea and vomiting
- Light-headedness or sudden dizziness

WOMEN:

- Feeling unusually tired for no reason, sometimes for days
- Pain in the back, shoulders, and jaw



**Some NSTEMIs
have no symptoms
at all**



Chest Pain Patients Get to the ED Quickly

>10 hours

30%

< 2 hours

25%

6-10 hours


10%

2-3 hours

24%

4-6 hours

11%





OBSERVATION

DISCHARGE



ED

ADMIT

CATH LAB



Universal Definition of MI

(Joint ESC/ACCF/AHA/WHF Task Force)

MI
is: **Myocardial necrosis in a clinical setting consistent with myocardial ischemia**

Rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile with at least one of the following:

- Symptoms of ischemia
- New or presumed new significant ST-segment changes or new left bundle branch block
- Development of pathological Q waves in the ECG
- Imaging evidence: loss of myocardium or wall motion abnormality
- ID of intracoronary thrombus by angiography or autopsy

Cardiac death with symptoms of ischemia

PCI patients: Cardiac marker elevations of 5 x 99th percentile or rise of 20%

Stent thrombosis identified by angiography or autopsy

CABG patients: Cardiac marker elevations of 10 x 99th percentile



Important to Remember



A positive Tn is no longer an MI

A positive Tn means cardiac damage

- It could be an MI
- It could be something else...



Non-ACS/HF Tn Elevations

Cardiac and Vascular

- Acute aortic dissection
- Cerebrovascular accident
 - Ischemic stroke
 - Intracerebral hemorrhage
 - Subarachnoid hemorrhage

Respiratory

- Acute PE, ARDS

Muscular Damage

Cardiac Inflammation

- Endocarditis, Myocarditis, Pericarditis

Infectious

- Sepsis, Viral illness, Kawasaki disease. Apical ballooning syndrome. Thrombotic thrombocytopenic purpura, Rhabdomyolysis, Birth complications in infants (low birth weight, preterm)

Acute Complications of Inherited Disorders

- Neurofibromatosis, Duchenne muscular dystrophy, Klippel-Feil syndrome

Environmental Exposure

- Carbon monoxide, Hydrogen sulfide, Colchicine

Chronic Disease

- ESRD, Cardiac infiltrative disorders (Amyloidosis, Sarcoidosis, Hemochromatosis), Scleroderma, Hypertension, Diabetes, Hyperthyroidism

Iatrogenic Disease

- Invasive procedures (Heart transplant, Congenital defect repair, Lung resection, ERCP, RFCA)
- Noninvasive procedures (Cardioversion, Lithotripsy)
- Pharmacological sources (Chemotherapy, Other medications)

Myocardial Injury


- Blunt chest injury, Endurance athletes, Envenomation (Snake, Jellyfish, Spider, Centipede, Scorpion)



How to Best Use TnI Results

99th Percentile Value: Apparently healthy population, results are typically close to zero

AMI Cutoff: Value that determines if a patient is experiencing an AMI based on WHO criteria



Serial draws are recommended to detect temporal rise and fall of troponin-I levels characteristic of MI, and should be used in conjunction with other information such as other cardiac markers, ECG, clinical symptoms, etc.



How to Best Use TnI Results

99th Percentile Value: Apparently healthy population, results are typically close to zero

AMI Cutoff: Value that determines if a patient is experiencing an AMI based on WHO criteria



Serial draws are recommended to detect temporal rise and fall of troponin-I levels characteristic of MI, and should be used in conjunction with other information such as other cardiac markers, ECG, clinical symptoms, etc.



The American College of Emergency Physicians (ACEP) Guidelines for Non-ST Elevation Chest Pain Patients

All patients

- No rule-in recommendation.
- For rule-out:
A single negative CK-MB mass,
Troponin I or Troponin T
measured 8-12 hours after
symptom onset.


Early presenters

(<6-8 hours after symptom onset)

- A negative myoglobin in conjunction with a negative CK-MB mass, or negative Troponin when measured at baseline and 90 minutes.
- A negative 2-hour delta CK-MB mass in conjunction with a negative 2-hour delta Troponin.



How to Best Use TnI Results



FOR DISCUSSION PURPOSES ONLY. *The temporal release patterns of modern troponin assays have not been conclusively established in the literature. Individual patients may exhibit unique cardiac marker profiles.*



Rapid Disposition Algorithm and Strategy

Data from three Dallas-area hospitals:

Medical Center of Arlington

~ one hour intervals

Plaza Medical Center

~ two-hour intervals

Medical City Dallas

~ three hour intervals

If any of the three criteria below were met, the patient was considered positive for an MI:

1

A TnI \geq 0.4 ng/mL on any draw

2

A doubling of myoglobin between sequential draws with any detectable TnI by the last draw

3

A doubling of myoglobin between sequential draws with a 50% or greater increase in CK-MB without detectable TnI on any of the draws

Testing performed on the Alere Triage platform.



	SINGLE DRAW		SERIAL DRAWS	
	0.05 ng/mL	0.4 ng/mL	0.05 ng/mL	0.4 ng/mL
Sensitivity (%)	79.7	57.4	97.3	68.2
Specificity (%)	96.1	99.8	95.0	99.8
Accuracy (%)	95.6	98.6	95.1	98.9
PPV (%)	37.2	87.6	36.4	89.4
NPV (%)	99.4	98.8	99.9	99.1

Straface , AL *et al* Am. J. Clin. Path. (2008) 129:788-795

Clinical Value of Rapid Disposition Algorithm


5,241
patients

30,087
test results
generated

1.9
draws per
patient



5.7
test results
per patient

Non-diseased vs. Diseased diagnosis



		+	-	Total
Panel Results	+	145	12	157
	-	3	5041	5044
	Total	148	5053	5201

Improving Patient Flow in Acute Coronary Syndromes in the Face of Hospital Crowding




In the post-implementation period there was:

- 20% reduction in hospital LOS.
- 33% reduction in ED LOS
- 62% decrease (5% vs. 1.9%) in 30-day mortality



POCT Alone is Not Enough



Ryan, R.J. *et al.* Ann Em Med (2009), 53:321-328



Impact on ED Operations

	Admitted	Discharged
Disposition	↓ -7.8 minutes	↓ -20.4 minutes
Departure	↓ -9 minutes	↓ -7.2 minutes

Ryan, R.J. *et al.* Ann Em Med (2009), 53:321-328

Why knowing now matters in the ED - Sepsis

Definition of Sepsis

Systemic, deleterious host response to infection

- Presence (probable or documented) of infection together with systemic manifestations of infection which may include:

Fever

>38.3°C

or

Core temp

<36°C



HR >90/min
or more than
2SD above
normal for age

Altered Mental Status

and/or

Tachypnea

WBC count

>12,000/mm³ or
<4,000/mm³
or >10% immature forms

Hyperlactatem ia

> 1mmol/L


Plasma Procalcitoni n

more than 2SD
above normal



Mortality Rates

- Sepsis remains the leading cause of death in critically ill patients in the United States.
- Each year 750,000 people will develop sepsis.
- Leading non-cardiac cause of death in ICUs
- Mortality rates between 28-38%



NIH HIV AIDS Statistics, 2001.

Breast Cancer Figures 2005-2006

Angus DC, Linde-Zwirble WT, Lidicker J et al. Crit Care Med. (2001) 29:1303-10.



Diagnostic Criteria for Sepsis

Infection, documented or suspected, and some of the following:

General

Inflammatory

Hemodynamic


**Organ
Dysfunction**

Tissue Perfusion

Lactate



Lactate Predicts Mortality



Initial Resuscitation and Infection Issues - The Overall Goal

Protocolized resuscitation of patients with sepsis-induced hypoperfusion

- Hypotension after initial fluid challenge or
- Lactate > 4 mmol/L

6-hour goals

- CVP 8-12 mm Hg
- MAP > 65 mm Hg
- Urine output >0.5 mL* kg*hr
- ScvO₂ 70% or SvO₂ 65%

Normalize an elevated lactate

Improve Patient Outcomes

Lactate clearance is associated with improved patient outcome.

Lactate measurement is associated with increased risk of death independent of other aspects of sepsis bundle guidelines.

Point-of-care measurements of lactate are faster than central laboratories.

- **May be beneficial for serial measurements.**



Nguyen HB, Rivers EP, Knoblich BP *et al.* *Crit Care Med.* (2004) 32:1637-42.
Afessa B, Keegan MT, Schramm GE *et al.* *Crit Care Med.* (2011) 15(Suppl 1): P286.
Boldt J, Kumle B, Suttner S *et al.* *Acta Anaesthesiol Scand.* (2001) 45:194–9.

Implementation of the Surviving Sepsis Protocols

**15,775 patients at
252 participating
Surviving Sepsis sites¹**

**Unadjusted hospital
mortality
decreased
from 37% to 30.8%
over a 2-year period**

¹Intensive Care Med (2010) 36:222-231.

Implementation of the Surviving Sepsis Protocols

**15,775 patients at
252 participating
Surviving Sepsis sites¹**

**Unadjusted hospital
mortality
decreased
from 37% to 30.8%
over a 2-year period**

**33-month study period
at Mayo-MN²**

**Bundle
compliance rose
from
12.7% to 52.7%**

**Mortality declined
from 30.3% to 22%**

¹Intensive Care Med (2010) 36:222-231.

². Crit Care Med (2011) 39:252-258,

Implementation of the Surviving Sepsis Protocols

**15,775 patients at
252 participating
Surviving Sepsis sites¹**

**Unadjusted hospital
mortality
decreased
from 37% to 30.8%
over a 2-year period**

**33-month study period
at Mayo-MN²**

**Bundle
compliance rose
from
12.7% to 52.7%**

**Mortality declined
from 30.3% to 22%**

**Medical City Plano (TX)
evaluation³**

**Mortality in the
non-bundle group:
61.1%**

**Mortality in the
bundle group: 20%**

¹Intensive Care Med (2010) 36:222-231.

² Crit Care Med (2011) 39:252-258,

³ Ann Pharmacother (2010) 44:1733-1738



Rapid Lactates for Septic Patients: CMS Core Measure

SEP-1: Early Management Bundle, Severe Sepsis/Septic Shock Specifications Manual for National Hospital Inpatient Quality Measures

Discharges 10-01-15 (4Q15) through 06-30-16 (2Q16) SEP-3

Severe Sepsis

Within 3 hours of presentation time, patient must have:

- Lactate drawn
- Blood cultures drawn
- Broad-spectrum antibiotics administered
- Within 6 hours of presentation time:
- Repeat lactate must be drawn if the initial lactate was >2.0 mmol/L

Septic Shock

Within 3 hours of presentation time, patient must have:

- Resuscitation with 30ml/kg of crystalloid fluid for hypotension or lactate ≥ 4 mmol /liter
- Within 6 hours of presentation time (and only if hypotension persists after fluid administration):
 - Vasopressors
 - Reassessment of volume status and tissue perfusion must be documented in the medical record

INITIATED ON OCTOBER 1, 2015

Point-of-Care Analyte Benefits

A 2010 study published in the *Journal of Emergency Medicine* found that point-of-care testing provided a reliable and feasible way to measure serum lactate at the bedside.¹

Point-of-care lactate is useful in the diagnosis of sepsis at the bedside

- Recommended for institutions where clinical decisions are limited by lack of laboratory infrastructure or reliability.²



¹Shapiro NI, Fisher C, Donnino M *et al.* *J Emerg Med.* (2010) 39:89-94.

²Moore CC, Jacob ST, Pinkerton R *et al.* *Clin Infect Dis.* (2008) 46:215-22.



Turnaround Time

- Serum lactate must be available with rapid turnaround time (within minutes) to effectively treat severely septic patients.
- An arterial blood gas analyzer located in the clinical laboratories usually accomplishes this.
- Hospitals should invest in adequate equipment in to meet present standards of care for septic patients.





Don't Forget Creatinine

Prior to any imaging procedure that requires the use of a contrast dye, a measurement of creatinine levels is required to confirm kidney function.

POC creatinine can play a key role in these diagnostic pathways.



Why knowing now matters in the ED - Infectious Diseases



Advantages of Rapid Testing for Infectious Diseases

Better directed therapy to reduce

- antibiotic resistant
- hospital length-of-stay


Less adverse consequences

Reduced length-of-stay in emergency department

Timely application of appropriate Infection control procedures


Teachable moment

Results – Flu Negative





Bonner, et al, Pediatrics (2003) 112:363-367

Results – Flu Positive



* - $p \leq 0.001$

Key Operational Metrics



Why molecular?

The power of sample amplification

Conventional **non-molecular** methods can have suboptimal limits of detection.

Samples with low viral or bacterial load could result in a false negative.

With **molecular**, even a few hundred infectious particles can be amplified billions of times!

Amplification increases likelihood of detection, and may compensate for suboptimal sample collection.

Positive Patient Sample

Conventional Non-Molecular Methods

Amplified

False Negative

Detection Threshold

True Positive

Flu Clinical Trial Results: vs PCR



Alere™ i Influenza A & B against RT-PCR for Influenza A

Alere™ i Influenza A & B – Flu A	RT-PCR		
	Positive	Negative	Total
Positive	147	11	158
Negative	8	464	472
Total	155	475	630
Positive Percent Agreement: 147/155 94.8%		(95%CI: 90.1%–97.4%)	
Negative Percent Agreement: 464/475 97.7%		(95%CI: 95.9%–98.7%)	

Alere™ i Influenza A & B against RT-PCR for Influenza B

Alere™ i Influenza A & B – Flu B	RT-PCR		
	Positive	Negative	Total
Positive	123	3	126
Negative	2	500	502
Total	125	503	628
Positive Percent Agreement: 123/125 98.4%		(95%CI: 94.4%–99.6%)	
Negative Percent Agreement: 500/503 99.4%		(95%CI: 98.3%–99.8%)	

Every Minute Counts at the Point of Care





Why Test?

Knowledge of a Positive Test Has Been Shown to:

Limit unnecessary antibiotic use


Limit unnecessary diagnostic procedures

Increase the appropriate use of antivirals



Alere™ i is *significantly faster* than other molecular methods and more accurate than conventional rapid testing giving you the *confidence* to make effective *patient management decisions sooner*.

Summary of the Recommendations



Routine screening in all healthcare settings with undiagnosed prevalence $\geq 0.1\%$ for patients aged 13 to 64 years

Repeat testing should be performed at least annually for those determined to be high-risk

Routine screening for all pregnant women

Screening should be voluntary using opt-out consent



ACEP 2014 Policy Statement

Early diagnosis and treatment of HIV

- Prolongs life
- Reduces transmission
- Is a cost-effective public health intervention

Candidates for HIV screening:

- All from 15-65 years old
- High risk adolescents and elderly
- All pregnant women with unknown HIV status

ED HIV screening programs are best when:

- Local prevalence of HIV is $> 0.1\%$
- Procedures are practical and feasible
- Integrated with resources of the healthcare system (linkage to care)



Is Rapid Testing in the ED Feasible?

PROS

- High-risk populations use the ED as their sole source for medical care
- Seroprevalence is relatively high ($\geq 0.1\%$ per CDC guidance) and this affords an outstanding opportunity to determine risk and to test for HIV
- Rapid tests are quick and accurate
- Growing experience and body of literature demonstrating clinical and cost effectiveness

CONS

- Perceptions regarding ED-based prevention efforts vary
- Program implementation will vary depending on resources and site
- Limited comparative data
- Funding

Benefits of Early Diagnosis of HIV Infection

Reduction of high-risk behavior¹

Reduces the risk of forward transmission:

Individuals with acute HIV infection are 43 times more contagious than chronically infected HIV patients²

Allows individuals with HIV to seek treatment earlier which:^{3,4,5}

- Will improve their health
- Reduces the risk of premature death
- Reduces their viral load, reducing the risk of forward transmission

¹Marks G, *et al.* JAIDS (2005) 39:446-453

²Pinkerton, S.D. AIDS Behav. (2008 September) 12: 677-684. doi:10.1007/s10461-007-9329-1.

³Moyer VA, *et al.* Ann Intern Med. (2013) 159:51-60.

⁴CDC. MMWR (2011) ;60(47):1618-23.

⁵Starting antiretroviral treatment early improves outcomes for HIV infected individuals.


<http://www.nih.gov/news/health/may2015/niaid-27.htm>

FOR EXTERNAL USE, PRINT/DISTRIBUTION PERMITTED



Performance of Alere Determine™ HIV-1/2 Ag/Ab Combo

Number of Early HIV Infection Samples Identified (*confirmed by NAAT*)



Is POCT in the ED Cost Effective?

Is POCT Cost Effective?

Review article covering the value of POCT for:

ACS

VTE

Sepsis

Stroke

“with respect to the numerous manual steps to be performed in transferring a blood sample to the central laboratory and to retrieve the results consecutively, the total costs of POCT devices tend not to exceed those of central analysis.”

POC staff do need to learn how to operate the POCT, but expediting patient flow might reduce the strain on this staff.

“When used effectively and in the appropriate context, POCT has been shown to reduce delays to treatment initiation in the critically ill, improve outcomes, increase timely patient discharge rates, and decrease total length of stay. Elevated costs of POCT per analysis seem to be outweighed by the total gain of expedited patient flow in the appropriate setting.”


Thank
You



Questions?

ellis.jacobs@alere.com

© 2018 Abbott. All rights reserved. All trademarks referenced are trademarks of the Abbott group of companies. All other trademarks referenced are trademarks of their respective owners. SAHIGHR- 0068 vD 3/18



Abbott